Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Discounted Cash Flow Valuation of Innoviva, Inc.
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
The average Net Margin over the past 5 years is +78.73%.
The trend of Net Margin over the past 5 years is -6.58%.
The average ROA over the past 5 years is +39.04%.
The trend of ROA over the past 5 years is -3.38%.
The average ROE over the past 5 years is +60.73%.
The trend of ROE over the past 5 years is -3.92%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
The Debt/FCF trailing twelve month is 3.90.
The trend of Debt/FCF over the past 5 years is -0.30.
Graham’s Stability measure stands at 0.80.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
The Revenue CAGR over the past 5 years is +8.81%.
The trend of Revenue growth rate over the past 5 years is -96.69%.
The Earnings CAGR over the past 5 years is +9.78%.
The trend of Earnings growth rate over the past 5 years is -32.84%.
The Equity CAGR over the past 5 years is -.
The trend of Equity growth rate over the past 5 years is -41.37%.
The FCF CAGR over the past 5 years is +7.3%.
The trend of FCF growth rate over the past 5 years is -67.97%.